Ophthalmology

Bausch + Lomb's VICTUS Femtosecond laser platform has received CE Mark for corneal incisions made during cataract surgery, according to a Laser Focus World report.

NovaBay Pharmaceuticals, an Emeryville, Calif.-based biotechnology company, has enrolled its first patients in a global Phase 2b clinical trial designed to test its Auriclosene Ophthalmic Solution as a treatment for a highly contagious form of pink-eye.

The FDA has granted Bausch + Lomb approval for PROLENSA, its anti-inflammatory prescription eye drop for patients that have undergone cataract surgery.

Aiello Eye Institute in Yuma, Ariz., has announced that it has added optical services to the LASIK, cataract surgery and various ophthalmology options offered at its Foothills location.

Colorado University School of Medicine in Aurora has created the Sue Anschutz-Rodgers Endowed Chair in Retinal Diseases in honor of a $2 million donation, according to a Denver Journal report.

Aerie Pharmaceuticals has named David Epstein, MD, a board-certified ophthalmologist, as chairman of the company's scientific advisory board.

The LENSAR Laser System, designed to help surgeons perform precise corneal and arcuate incisions during refractive cataract surgery, has earned FDA 510(k) clearance.

InSite Vision has earned $15 million for future royalties of Besivance, its pink-eye antibacterial eye drop, according to a San Francisco Business Times report.

Medifirst Solutions, a New Jersey and Florida-based distributor of healthcare products and services, has announced the addition of Kenneth R. Pearlberg, MD, to its advisory board.

Devers Eye Institute in Portland, Ore., offers its patients corneal crosslinking, a treatment designed to slow post-LASIK ectasia and keratoconus, according to The Lund Report.